Xenon Pharmaceuticals Inc. — Q1 2019 Form 10-Q
Business context and reporting period. Unaudited results for the three months ended March 31, 2019, reported in U.S. dollars. Xenon is a clinical-stage biopharmaceutical company developing neurology therapies, particularly for epilepsy. It had no significant product revenue and reported no collaboration revenue in either Q1 2019 or Q1 2018.
Financial highlights
| Metric | Q1 2019 / March 31, 2019 | Comparable / December 31, 2018 |
|---|---|---|
| Revenue | None reported from collaborations; no significant product revenue | None reported from collaborations in Q1 2018 |
| Research and development expense | $9.1 million | $5.6 million in Q1 2018 |
| General and administrative expense | $2.6 million | $2.2 million in Q1 2018 |
| Total operating expense / operating loss | $11.8 million / $(11.8) million | $7.8 million / $(7.8) million in Q1 2018 |
| Net loss | $(11.3) million; $(0.42) per common share, basic and diluted | $(3.8) million; $(0.21) per common share in Q1 2018 |
| Cash and cash equivalents | $52.2 million | $67.8 million at December 31, 2018 |
| Marketable securities | $58.2 million | $51.6 million at December 31, 2018 |
| Operating cash used | $8.7 million | $8.2 million in Q1 2018 |
| Long-term loan carrying value | $15.1 million | $15.0 million at December 31, 2018 |
Cash, cash equivalents and marketable securities totaled $110.4 million at quarter-end, down from $119.3 million at year-end. Current assets were $112.0 million and current liabilities were $6.4 million. The $15.5 million term loan bears an effective interest rate of 9.53%; scheduled principal repayments begin in 2020, and a $1.0 million final payment fee is excluded from the stated principal schedule. The company reported covenant compliance at March 31.
With no reported revenue, profit margins are not meaningful. Net loss attributable to common shareholders was $10.9 million in Q1 2019; total net loss was $11.3 million, including $0.4 million attributable to preferred shareholders.
Material changes versus Q1 2018
- Operating expenses rose $4.0 million, or about 51%. R&D increased $3.6 million, primarily with higher spending on XEN1101, XEN901 and XEN496; G&A rose $0.4 million, primarily from intellectual-property legal and business-development costs.
- Net loss widened by $7.6 million. The comparison is affected by a $4.4 million one-time gain recorded in Q1 2018 on termination of the Teva collaboration; there was no corresponding gain in Q1 2019.
- Interest income increased to $0.7 million from $0.1 million, while interest expense increased to $0.4 million from $0.2 million. Foreign exchange moved from a $0.3 million loss to a $0.1 million gain.
- Operating cash use was relatively similar year over year. Investing cash flow changed from $5.0 million provided in Q1 2018 to $7.0 million used in Q1 2019, mainly because purchases of marketable securities exceeded proceeds from maturities.
Outlook, management commentary and risks
- Management expected significant expenses and operating losses for the foreseeable future, including the next 12–24 months, with R&D expected to remain the largest expense category. The company said quarter-end cash and securities were expected to fund operating and capital needs for at least 12 months from the report date; management cautioned that this estimate depends on assumptions and funds could be used sooner.
- XEN1101: Phase 2b trial in approximately 300 adults with focal epilepsy was underway, with site selection and enrollment in progress. Top-line results were anticipated in the second half of 2020, depending on enrollment.
- XEN496: Pediatric formulation work was ongoing; a healthy-adult study was expected to begin in Q3 2019, and an IND filing to support a Phase 3 KCNQ2-EE trial was expected in Q4 2019. The FDA had indicated that a pivotal study of approximately 20 patients might be considered adequate, subject to development results and safety.
- XEN901: Regulatory feedback on advancing into pediatric SCN8A-EE was expected in Q2 2019; further clinical development planning, pediatric formulation work and juvenile toxicology studies were ongoing.
- XEN007: The company was considering development strategies, including at least one Phase 2-or-later orphan-neurology trial, with initiation anticipated in 2019.
- Key risks include clinical or regulatory failure and delay, difficulty enrolling patients in rare-disease trials, reliance on collaborators and third-party manufacturers, intellectual-property challenges, and the need for additional financing. Future equity financing could dilute shareholders; debt or collaboration financing could impose restrictions or require rights concessions. The company had no committed external capital beyond potential collaborator milestone payments.
- There were no material changes to contractual commitments from the 2018 Form 10-K. No material legal proceedings were reported. Management said disclosure controls were effective and reported no material change in internal control over financial reporting.
- The company adopted the new lease standard on January 1, 2019, recognizing a right-of-use asset and lease liability; adoption produced a $0.2 million cumulative adjustment to opening retained earnings and did not materially affect operations or cash flows.
Most important facts for investors to verify
- Whether the stated minimum 12-month liquidity runway remains supported by actual cash burn, trial costs and updated development plans.
- Enrollment progress and timing for the XEN1101 Phase 2b trial, and whether the anticipated second-half 2020 results timetable changed.
- Progress against the XEN496 formulation, healthy-volunteer study and IND milestones, including any updated FDA requirements.
- Clinical and regulatory progress for XEN901 and XEN007, including trial-start timing and any additional study requirements.
- Loan covenants, repayment schedule and final payment fee, along with potential financing needs and resulting dilution or restrictions.